{"id":3048,"date":"2025-12-02T08:36:25","date_gmt":"2025-12-02T08:36:25","guid":{"rendered":"https:\/\/wallstreetendeavor.com\/?p=3048"},"modified":"2025-12-09T08:36:31","modified_gmt":"2025-12-09T08:36:31","slug":"uk-us-zero-tariff-deal-on-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/wallstreetendeavor.com\/de\/pharmaceutical\/uk-us-zero-tariff-deal-on-pharmaceuticals\/","title":{"rendered":"UK-US Zero Tariff Deal on Pharmaceuticals"},"content":{"rendered":"

The UK and the US have struck a deal that guarantees zero tariffs on British pharmaceuticals<\/strong> shipped to America for the next three years.<\/p>\n\n\n\n

Under the terms, the UK will raise the price threshold for new treatments and increase overall NHS spending on medicines from 0.3% of GDP to 0.6% over the next decade. In return, US import taxes on UK-made drugs will remain at zero, protecting a key export worth at least \u00a35 billion a year.<\/p>\n\n\n\n

Business and Trade Secretary Peter Kyle<\/strong> called it a \u201cguarantee that UK pharmaceutical exports will enter the US tariff free, protecting jobs, boosting investment and paving the way for the UK to become a global hub for life sciences.\u201d<\/p>\n\n\n\n

This zero-tariff deal follows repeated threats from President Donald Trump to impose tariffs of up to 100% on branded drug imports<\/span><\/a>. US officials argued that American consumers were effectively subsidizing the cost of medicines for other developed nations and sought to bring more production stateside.<\/p>\n\n\n\n

NICE, the UK\u2019s advisory body, expects three to five additional medicines a year to be approved, potentially raising costs by around \u00a33 billion. <\/p>\n\n\n\n

While some see this as a necessary investment in innovation, others, like Sally Gainsbury from the Nuffield Trust think tank<\/strong>, warn it\u2019s \u201cbad news\u201d given budget restraints. “The extra cost will need to be fully-funded by the Treasury,” she said, adding that stretched budgets may be better spent on GP services or reducing hospital backlogs.<\/p>\n\n\n\n

Pharmaceutical investment in the UK has seen turbulence recently. GSK, Merck, and AstraZeneca all shifted focus to the US<\/span><\/a>, pausing or cancelling UK expansions. This deal could reverse that trend: Bristol Myers Squibb has already indicated it could invest over $500 million in the UK over the next five years in research, development, and manufacturing.<\/p>\n\n\n\n

William Bain from the British Chambers of Commerce<\/strong> called the deal \u201ca real win,\u201d highlighting its potential to boost exports, investment, and the UK\u2019s competitive position in global life sciences.<\/p>\n\n\n\n

For investors, this agreement signals stability in UK pharmaceutical exports to the US and could create a more predictable environment for both domestic and international pharma companies.<\/p>\n\n\n\n

With the UK bolstering its life sciences sector, potential openings in manufacturing, R&D, and supply chain investments are starting to take shape.<\/p>","protected":false},"excerpt":{"rendered":"

The US and UK have reached a zero-tariff deal on pharmaceuticals, but the real impact can be felt across investment, innovation, and public health.<\/p>","protected":false},"author":2,"featured_media":3049,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[48,32,55,61,57,7],"tags":[64,68,69,72,33,31],"class_list":["post-3048","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotech","category-pharma-general","category-pharma-industry","category-latest-global-stock-market-news","category-pharma-investments","category-pharmaceutical","tag-biotech","tag-finance","tag-general","tag-industry","tag-investing","tag-pharmaceutical"],"acf":{"featured_video_oembed":"","featured_post_summary":"","post_source":""},"_links":{"self":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/3048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/comments?post=3048"}],"version-history":[{"count":1,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/3048\/revisions"}],"predecessor-version":[{"id":3050,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/3048\/revisions\/3050"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/media\/3049"}],"wp:attachment":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/media?parent=3048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/categories?post=3048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/tags?post=3048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}